3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Spinocerebellar Degenerations
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
124
Cisplatin
27
lenvatinib
24
Carboplatin
24
Paclitaxel
19
Docetaxel
16
Fluorouracil
13
Capecitabine
11
Pemetrexed
10
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
olaparib
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
vicriviroc
×
Clear all
NCT03631407
2024-11-21
MK-7690-046
Merck Sharp & Dohme LLC
Phase 2
Completed
41 enrolled
20 charts